Minyanville By: Brett Chase September 7, 2012
Peregrine CEO Steven King is hoping the study results will help him lock up a partner to pay for the next phase of clinical trials. King recently told Minyanville that he’s had 15 meetings with potential development partners. A partner would help Peregrine pay for the third and final phase of studies generally needed for US approval of a new treatment. King said he hopes to find a partner that would allow Peregrine to retain some of the US sales rights for the drug if it should ever be approved.
“We are currently in discussions with several potential pharmaceutical partners who have expressed great interest in our bavituximab oncology program,” King says in a statement Friday.